Shares of Evotec AG (NASDAQ:EVO - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $4.26, but opened at $3.71. Evotec shares last traded at $3.71, with a volume of 133,487 shares.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. Deutsche Bank Aktiengesellschaft raised Evotec from a "sell" rating to a "hold" rating in a research note on Thursday, April 24th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $5.93.
Check Out Our Latest Research Report on Evotec
Evotec Price Performance
The company has a 50-day moving average of $4.11 and a 200 day moving average of $4.01. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.93 and a current ratio of 2.03.
Institutional Investors Weigh In On Evotec
Institutional investors have recently bought and sold shares of the stock. Valeo Financial Advisors LLC purchased a new stake in shares of Evotec in the 2nd quarter worth approximately $43,000. UMB Bank n.a. purchased a new stake in Evotec during the 2nd quarter valued at $56,000. ABC Arbitrage SA purchased a new stake in Evotec during the 1st quarter valued at $260,000. DCF Advisers LLC boosted its stake in Evotec by 227.0% during the 1st quarter. DCF Advisers LLC now owns 751,579 shares of the company's stock valued at $2,510,000 after purchasing an additional 521,708 shares during the last quarter. Finally, CSS LLC IL purchased a new stake in Evotec during the 4th quarter valued at $50,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.
Evotec Company Profile
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
Featured Stories
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
